Table 1.
Antiproliferative effects of compounds against MV-4-11 and MV-4-11/quizartinib cells
| Compound | IC50 (nM, Mean ± SD) | RF | |
|---|---|---|---|
|
| |||
| MV-4-11 | MV-4-11/quizartinib | ||
| Quizartinib | 0.2 ± 0.1 | 181.8 ± 15.5 | 1009.4 |
| Crenolanib | 2.1 ± 0.1 | 13.7 ± 0.9 | 6.6 |
| Gilteritinib | 1.5 ± 0.6 | 47.0 ± 28.0 | 31.8 |
| Sunitinib | 4.1 ± 0.1 | 23.3 ± 0.8 | 5.6 |
| Sorafenib | 0.7 ± 0.1 | 1116.0 ± 152.7 | 1536.8 |
| Paclitaxel | 0.4 ± 0.1 | 0.2 ± 0.1 | 0.5 |
Notes: MV-4-11 and MV-4-11/quizartinib cells were treated with different concentrations of compounds for 72 h. Cell survival was analysed by MTT assay. Data are presented as the means ± SD of three independent experiments. RF, resistance factor.